GSK 2696277

Drug Profile

GSK 2696277

Latest Information Update: 11 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fondazione Telethon; GlaxoSmithKline; Ospedale San Raffaele
  • Class Gene therapies; Stem cell therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Beta-thalassaemia

Most Recent Events

  • 12 Sep 2017 GlaxoSmithKline plans a phase II trial for Beta-thalassaemia (In children, In adults, In elderly) (NCT03275051)
  • 01 Mar 2016 Phase-I clinical trials in Beta-thalassaemia (Parenteral) (GlaxoSmithKline pipeline, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top